Literature DB >> 33712036

Predictive value of C-reactive protein to albumin ratio as a biomarker for initial and repeated intravenous immunoglobulin resistance in a large cohort of Kawasaki disease patients: a prospective cohort study.

Xiaoliang Liu1,2,3, Lin Wang4, Kaiyu Zhou1,2,3,5, Shuran Shao1,6, Yimin Hua1,2,3,5, Mei Wu1,6, Lei Liu1,6, Chuan Wang7,8,9,10.   

Abstract

BACKGROUND: Intravenous immunoglobulin (IVIG) resistance prediction is one pivotal topic of interests in Kawasaki disease (KD). This study aimed to prospectively investigated the value of C-reactive protein-to-albumin (CAR) in predicting both initial and repeated IVIG resistance in patients with KD, and to test the hypothesis that CAR was more valuable or accurate than either C-reactive protein (CRP) or albumin (ALB) alone in IVIG resistance prediction.
METHOD: A prospective cohort study involving 550 patients with KD was conducted. The clinical and laboratory data were compared between IVIG-response group and IVIG-resistance group. Multivariate logistic regression analysis was performed to identify the independent risk factors of initial/repeated IVIG resistance. Receiver operating characteristic (ROC) curves analysis was applied to assess the validity of CAR, CRP and ALB in predicting both initial and repeated IVIG resistance.
RESULTS: CAR was significantly higher in IVIG non-responders and was identified as independent risk factor for both initial and repeated IVIG resistance in KD. The best cut-off value of CAR for initial and repeated IVIG resistance prediction was 2.07 and 3.34, with a corresponding sensitivity of 0.610 and 0.548, a specificity of 0.552 and 0.813, respectively. The value of CAR was not better than either CRP or ALB alone for both initial and repeated IVIG resistance prediction.
CONCLUSION: A higher CAR was an independent risk factor for both initial and repeated IVIG resistance. However, similar with that of CRP or ALB, the predictive value of CAR was not good enough for both initial and repeated IVIG resistance prediction in KD.

Entities:  

Keywords:  C-reactive protein to albumin ratio; Intravenous immunoglobulin resistance; Kawasaki disease

Year:  2021        PMID: 33712036      PMCID: PMC7953655          DOI: 10.1186/s12969-021-00517-1

Source DB:  PubMed          Journal:  Pediatr Rheumatol Online J        ISSN: 1546-0096            Impact factor:   3.054


  54 in total

1.  Influence of local reference populations on upper limits of normal for serum alanine aminotransferase levels.

Authors:  Brent A Neuschwander-Tetri; Aynur Unalp; Michael H Creer
Journal:  Arch Intern Med       Date:  2008-03-24

2.  Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment.

Authors:  Tetsuya Sano; Shunji Kurotobi; Kouji Matsuzaki; Takehisa Yamamoto; Ichiro Maki; Kazunori Miki; Shigetoyo Kogaki; Junichi Hara
Journal:  Eur J Pediatr       Date:  2006-08-01       Impact factor: 3.183

3.  Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study.

Authors:  Mary Beth Son; Kimberlee Gauvreau; Jane C Burns; Elena Corinaldesi; Adriana H Tremoulet; Virginia E Watson; Annette Baker; David R Fulton; Robert P Sundel; Jane W Newburger
Journal:  J Pediatr       Date:  2010-12-03       Impact factor: 4.406

4.  Prospective Evaluation of Neutrophil-to-lymphocyte Ratio and Platelet-to-lymphocyte Ratio for Intravenous Immunoglobulin Resistance in a Large Cohort of Kawasaki Disease Patients.

Authors:  Xiaoliang Liu; Kaiyu Zhou; Yimin Hua; Mei Wu; Lei Liu; Shuran Shao; Chuan Wang
Journal:  Pediatr Infect Dis J       Date:  2020-03       Impact factor: 2.129

5.  Cyclosporin A treatment for Kawasaki disease refractory to initial and additional intravenous immunoglobulin.

Authors:  Hiroyuki Suzuki; Masaru Terai; Hiromichi Hamada; Takafumi Honda; Tomohiro Suenaga; Takashi Takeuchi; Norishige Yoshikawa; Shoichi Shibuta; Masakazu Miyawaki; Ko Oishi; Hironobu Yamaga; Noriyuki Aoyagi; Seiji Iwahashi; Ritsuko Miyashita; Yoshihiro Onouchi; Kumiko Sasago; Yoichi Suzuki; Akira Hata
Journal:  Pediatr Infect Dis J       Date:  2011-10       Impact factor: 2.129

6.  A comparison of serum IL6 and CRP levels with respect to coronary changes and treatment response in Kawasaki disease patients: a prospective study.

Authors:  Alolika Nandi; Priyankar Pal; Surupa Basu
Journal:  Rheumatol Int       Date:  2019-07-13       Impact factor: 2.631

7.  Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.

Authors:  Adriana H Tremoulet; Sonia Jain; Preeti Jaggi; Susan Jimenez-Fernandez; Joan M Pancheri; Xiaoying Sun; John T Kanegaye; John P Kovalchin; Beth F Printz; Octavio Ramilo; Jane C Burns
Journal:  Lancet       Date:  2014-02-24       Impact factor: 79.321

8.  Gamma globulin re-treatment in Kawasaki disease.

Authors:  R P Sundel; J C Burns; A Baker; A S Beiser; J W Newburger
Journal:  J Pediatr       Date:  1993-10       Impact factor: 4.406

9.  Assessment of the Relationship Between C-Reactive Protein-to-Albumin Ratio and the Presence and Severity of Isolated Coronary Artery Ectasia.

Authors:  Seçkin Dereli; İdris Buğra Çerik; Ahmet Kaya; Osman Bektaş
Journal:  Angiology       Date:  2020-06-10       Impact factor: 3.619

Review 10.  Kawasaki disease: part II. Complications and treatment.

Authors:  Stephanie Bayers; Stanford T Shulman; Amy S Paller
Journal:  J Am Acad Dermatol       Date:  2013-10       Impact factor: 11.527

View more
  4 in total

1.  Overexpressed Neuropilin-1 in Endothelial Cells Promotes Endothelial Permeability through Interaction with ANGPTL4 and VEGF in Kawasaki Disease.

Authors:  Junhua Huang; Shuwan Zhang
Journal:  Mediators Inflamm       Date:  2021-08-13       Impact factor: 4.711

2.  Prediction of repeated intravenous immunoglobulin resistance in children with Kawasaki disease.

Authors:  Yaheng Lu; Tingting Chen; Yizhou Wen; Feifei Si; Xindan Wu; Yanfeng Yang
Journal:  BMC Pediatr       Date:  2021-09-16       Impact factor: 2.125

3.  Evaluation of laboratory predictors for intravenous immunoglobulin resistance and coronary artery aneurysm in Kawasaki Disease before and after therapy.

Authors:  Jie Liu; Bingbing Ye; Danyan Su; Suyuan Qin; Weiying Zhao; Yusheng Pang
Journal:  Clin Rheumatol       Date:  2022-09-21       Impact factor: 3.650

4.  Value of blood inflammatory markers for predicting intravenous immunoglobulin resistance in Kawasaki disease: A systematic review and meta-analysis.

Authors:  Chang Liu; Jiacheng Wu
Journal:  Front Pediatr       Date:  2022-08-23       Impact factor: 3.569

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.